oxaliplatin palmitate acetate

Oxaliplatin palmitate acetate (OPA) is a lipophilic platinum(IV) derivative of the chemotherapy drug oxaliplatin, designed to improve the efficacy and pharmacokinetic properties of platinum-based anticancer therapy. Unlike standard oxaliplatin, OPA incorporates both hydrophilic (acetate) and lipophilic (palmitate) axial ligands, which enhance its cellular uptake and facilitate incorporation into nanoparticle delivery systems. Preclinical studies have shown that OPA exhibits higher toxicity against various cancer cell lines—including pancreatic, lung, liver, ovarian, and colon cancers—compared to conventional oxaliplatin. The mechanism of action involves DNA platination leading to crosslinking that inhibits DNA replication and transcription in tumor cells. Notably, OPA is not considered a prodrug of oxaliplatin due to minimal conversion in vivo; it acts as an active agent itself[6][8]. Development has focused on improving antitumor activity while potentially overcoming resistance seen with other platinum drugs.

Other names

OPA